en English

APAC Circulating Tumor Cells Liquid Biopsy Market by 2029

Asia-Pacific Circulating Tumor Cells (CTC) Liquid Biopsy Market is growing with a CAGR of 28.4% in the forecast period of 2022 to 2029

Asia-Pacific circulating tumor cells (CTC) liquid biopsy market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 28.4% in the forecast period of 2022 to 2029 and is expected to reach USD 974.90 million by 2029 from USD 139.25 million in 2021. The high prevalence of chronic diseases and increasing R&D activities for its effective application is likely to be the major drivers which propel the demand of the market in the forecast period.

Request For a Sample Copy of This Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=asia-pacific-circulating-tumor-cells-ctc-liquid-biopsy-market

The liquid biopsy is a non-invasive blood test which detects circulating tumor cells and tumor DNA fragments which are released into the blood from primary tumors and metastatic sites. It is a simple and precise alternative to surgical biopsy procedure, which allows surgeon to detect cancer at a very early stage.

The circulating tumor cells are a rare sub-set of cells which function as a seed of metastases. It is found in blood of patients who have developed solid tumors. The testing of circulating tumor cells allows the detection and quantification of tumor cells in the blood of cancer patients. The various types of biological phenotypes of circulating tumor cells (CTCs) exits includes stem cell-like or mixed, mesenchymal or epithelial. These phenotypes are present in blood in a very small quantity. Due to which, their detection needs a phase of isolation-enrichment. After that, a second phase of detection.

The growing demand of circulating tumor cells (CTC) liquid biopsy because of their efficacy, high prevalence of cancer are the major drivers propelling the demand for circulating tumor cells (CTC) liquid biopsy market in the forecast period. However, the unclear regulatory and reimbursement scenario, shortage of skilled personnel is restraining the circulating tumor cells (CTC) liquid biopsy market growth in the forecast period.

The major companies which are dealing in the global circulating tumor cells (CTC) liquid biopsy market are Eurofins Genomics ( a subsidiary of Eurofins Scientific), MDx Health, Guardant Health, IMMUCOR, Thermo Fisher Scientific, Inc., Menarini Silicon Biosystems, QIAGEN, Exact Sciences Corporation, Myriad Genetics, Inc., LungLife AI, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc. , Natera Inc., ExoDx ( a subsidiary of Bio-Techne Corporation), Biocept, Inc., F. Hoffman-La Roche Ltd. ,FOUNDATION MEDICINE, INC., Lucence Health, Inc., Inivata Ltd, Biolidics Limited, Vortex Biosciences among others.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:- corporatesales@databridgemarketresearch.com